RxDoctor Payments Data

Douglas Sinclair, DO

Neuromuscular Medicine · West Columbia, SCNPI 1356404107

Payments from drug & device makers

$10,315in general payments, 2019–2025

Across 552 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$693
  • Acadia Pharmaceuticals Inc$580
  • Lundbeck LLC$467
  • AstraZeneca$439
  • EMD Serono, Inc.$415
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$1732%
  • Food & beverage$10,13598%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)73$1,213
Novartis39$693
Acadia Pharmaceuticals Inc31$580
Lundbeck LLC21$467
AstraZeneca(2 entities)20$439
EMD Serono, Inc.23$415
Neurocrine Biosciences, Inc.25$403
UCB, Inc.18$401
Teva Pharmaceuticals USA, Inc.28$363
Sanofi18$358
Eisai Inc.19$352
Amgen(2 entities)20$334
Genentech USA, Inc.17$289
Supernus Pharmaceuticals, Inc.15$284
Acorda Therapeutics, Inc15$272
Biogen13$266
TG Therapeutics, Inc.9$214
Argenx US, Inc.8$192
Pfizer11$183
Octapharma USA, Inc.2$182
Upsher-smith Laboratories LLC10$177
Mallinckrodt Enterprises LLC8$163
Lilly USA, LLC10$149
Otsuka America Pharmaceutical, Inc.6$122
Catalyst Pharmaceuticals, Inc.5$114
Takeda Pharmaceuticals U.S.A., Inc.4$96
Neurelis, Inc.5$96
SK Life Science, Inc.3$93
Bausch Health US, LLC5$91
Sunovion Pharmaceuticals Inc.6$89
Kyowa Kirin, Inc.5$85
MDD US Operations, LLC5$79
Amneal Pharmaceuticals LLC4$75
Merz Pharmaceuticals, LLC3$72
Impel Pharmaceuticals Inc.4$70
Biohaven Pharmaceutical Holding Company Ltd.3$64
CSL Behring3$58
Arbor Pharmaceuticals, Inc.4$56
Bristol Myers Squibb3$54
Vanda Pharmaceuticals Inc.2$54
Noctrix Health, Inc.1$52
Adamas Pharmaceuticals, Inc.3$46
Jazz Pharmaceuticals Inc.2$41
Mallinckrodt Hospital Products Inc.2$40
Johnson & Johnson2$38
Grifols USA, LLC2$34
Bayer2$33
ANI Pharmaceuticals, Inc.1$33
Avanir Pharmaceuticals, Inc.2$29
Insightec,inc1$25
Alnylam Pharmaceuticals Inc.1$24
Promius Pharma LLC1$24
Biohaven Pharmaceuticals, Inc.1$22
Tanabe Pharma America, Inc.1$19
Cycle Pharmaceuticals Inc1$17
Vertical Pharmaceuticals, LLC1$17
Avion Pharmaceuticals1$17
Portola Pharmaceuticals, LLC1$16
Zyla Life Sciences, Inc.1$12
Assertio Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$193,974
Medicare patients
856
Services billed
4,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab55$517,572
AustedoDeutetrabenazine25$176,219
RebifInterferon Beta-1a/Albumin14$164,814
Aimovig AutoinjectorErenumab-Aooe102$80,018
CopaxoneGlatiramer Acetate12$69,984
Teriflunomide17$69,268
FingolimodFingolimod Hcl28$54,412
Emgality PenGalcanezumab-Gnlm44$49,706
AmpyraDalfampridine11$46,826
Nurtec OdtRimegepant Sulfate41$43,874
GocovriAmantadine Hcl12$41,106
Memantine Hcl659$34,732
NeuproRotigotine13$23,833
QuliptaAtogepant17$22,827
RytaryCarbidopa/Levodopa13$21,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$363$246,20337 claims
EMD Serono, Inc.Rebif$415$164,81414 claims
Acorda Therapeutics, IncAmpyra$272$46,82611 claims
PfizerNurtec Odt$183$43,87441 claims
MDD US Operations, LLCGocovri$79$41,10612 claims
UCB, Inc.Neupro$401$23,83313 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$75$23,69640 claims
AbbVieQulipta$1,213$22,82717 claims
Eisai Inc.Fycompa$352$16,09314 claims
Upsher-smith Laboratories LLCTopiramate$177$3,591211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in West Columbia

Where these figures come from

Is this you, or does something look wrong? →